瑞视生物完成数千万元天使轮融资，董事长潘少辉控股68%

Core Insights - Ruisi Biotechnology (Hangzhou) Co., Ltd. has completed several million yuan in angel round financing [1] - The financing was led by Huafang Capital, with participation from Hangzhou Science and Technology Innovation Group [1] - The funds will be used to advance the company's iPSC-derived corneal endothelial cell therapy product pipeline and early-stage research driven by original technology [1] Company Overview - Ruisi Biotechnology was established in September 2024, focusing on the development of cell therapies and addressing significant unmet clinical needs in eye diseases [1] - The company is led by Pan Shaohui, who holds a 67.57% stake and serves as the chairman, manager, and financial officer [1] - The registered capital of the company is 1.48 million yuan [1] Technology and Development Focus - The company relies on its proprietary iPSC differentiation technology platform and AI + compound reprogramming technology platform [1] - Ruisi Biotechnology is dedicated to developing breakthrough cell therapies for urgent clinical needs in corneal and retinal diseases [1]